Mylan launches generic Yaz
Mylan has introduced its generic Yaz oral contraceptive (drospirenone and ethinyl estradiol tablets, 3 mg/0.02 mg). The drug is indicated to prevent pregnancy in women and treat acne vulgaris in menstruating women at least 14 years of age who want an oral contraceptive.
The generic Yaz joins Pittsburgh-based Mylan’s portfolio of more than 20 generic birth control medications in various dosage forms. Mylan said that its women’s health portfolio also continues to grow to offer patients options for managing their health at different stages of their lives.
Mylan’s generic Yaz had a U.S. market size of roughly $161 million for the 12 months ended Feb. 28, according to IQVIA data. Currently, Mylan has 204 abbreviated new drug applications awaiting FDA approval that represent roughly $90.8 billion in annual brand sales, according to IQVIA, Mylan said.
The generic Yaz joins Pittsburgh-based Mylan’s portfolio of more than 20 generic birth control medications in various dosage forms. Mylan said that its women’s health portfolio also continues to grow to offer patients options for managing their health at different stages of their lives.
Mylan’s generic Yaz had a U.S. market size of roughly $161 million for the 12 months ended Feb. 28, according to IQVIA data. Currently, Mylan has 204 abbreviated new drug applications awaiting FDA approval that represent roughly $90.8 billion in annual brand sales, according to IQVIA, Mylan said.